Brief: Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
31/03/2026 12:41
March 31 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PALVELLA THERAPEUTICS - NDA FOR QTORIN RAPAMYCIN FOR TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS ON TRACK FOR PLANNED SUBMISSION IN H2 2026 PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR CUTANEOUS VMS PLANNED FOR 2H 2026 PALVELLA THERAPEUTICS INC - PHASE 2 TRIAL OF QTORIN RAPAMYCIN FOR ANGIOKERATOMAS PLANNED FOR Q2 2026 Source text: ID:nGNXLkVh5 Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs